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Abstract
Essential tremor (ET), one of the most common adult-onset movement disorders, has been associated with cerebellar Purkinje cell degeneration and formation of
brainstem Lewy bodies. Recent findings suggest that genetic variants of the leucine-rich repeat and Ig domain containing 1 (LINGO-1) gene could be risk factors for
ET. The LINGO-1 protein contains both leucine-rich repeat (LRR) and immunoglobulin (Ig)-like domains in its extracellular region, as well as a transmembrane
domain and a short cytoplasmic tail. LINGO-1 can form a ternary complex with Nogo-66 receptor (NgR1) and p75. Binding of LINGO-1 with NgR1 can activate
the NgR1 signaling pathway, leading to inhibition of oligodendrocyte differentiation and myelination in the central nervous system. LINGO-1 has also been found
to bind with epidermal growth factor receptor (EGFR) and induce downregulation of the activity of EGFR–PI3K–Akt signaling, which might decrease Purkinje cell
survival. Therefore, it is possible that genetic variants of LINGO-1, either alone or in combination with other genetic or environmental factors, act to increase
LINGO-1 expression levels in Purkinje cells and confer a risk to Purkinje cell survival in the cerebellum.
Here, we provide a concise summary of the link between LINGO-1 and neurodegeneration and discuss various hypotheses as to how this could be potentially
relevant to ET pathogenesis.
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Introduction
Essential tremor (ET), one of the most common adult-onset
movement disorders, is characterized by action and postural tremor.
The prevalence is approximately 3–6% in people over the age of 65
years.1,2 ET patients usually have an 8–12-Hz kinetic tremor of the
arms, which is often accompanied with head and voice tremor.1 This
disorder is common across different races worldwide.2 ET patients
may also have other non-tremor features, including cognitive and
psychiatric symptoms.3,4 Based on pathological findings, some authors
have categorized ET into two groups: patients with cerebellar Purkinje
cell degenerative changes and patients with brainstem Lewy bodies.5–9
Family and twin studies have provided evidence for a genetic
contribution to ET, and segregation of ET within families containing
multiple affected members has been reported.10,11 The sequence
variant (rs9652490 G allele) of the leucine-rich repeat and Ig domain
containing 1 (LINGO-1) gene was recently identified to be a risk factor
for ET in American and European populations in a genome-wide
association study.12 Subsequently, most studies were able to replicate
this finding.12–21 Vilarino-Guell et al.15 showed that LINGO-1
variants, including rs9652490 and variants of LINGO2, a paralog of
LINGO-1, are associated with ET and PD. The LINGO-1 rs9652490
variant has been found to associate with ET in Europeans,14 North
Americans,16 and Singaporeans.17 In summary, six studies comprising
2834 ET patients and 16,638 healthy controls support a positive link
between the LINGO-1 variant rs9652490 and ET. However, four
studies comprising 711 ET patients and 2,186 healthy controls
reported negative results.18–21 Some authors have shown that ET is
also associated with additional LINGO-1 variants (rs488687, rs3144,
rs8028808, and rs12905478).15 The association of ET with other
LINGO-1 variants suggests possible allelic heterogeneity of the
LINGO-1 gene. Environmental factors may also play a role in ET.22
Here, we provide a concise summary of the link between LINGO-1
and neurodegeneration, and hypothesize its possible relevance to ET
pathogenesis.
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LINGO-1: Gene, Structure and Roles
The LINGO-1 gene, encoding a transmembrane glycoprotein, was
mapped to chromosome 15q24.23 The LINGO-1 protein belongs to
the larger leucine-rich repeat Ig protein family (also referred to as the
leucine-rich repeat transmembrane neuronal family (LRRTM) ).24,25
The LRRTM protein family was first described in 2003 and has
been linked with psychiatric diseases.26 This protein family possesses
three other human paralogs besides LINGO-1: Lingo-2, Lingo-3,
and Lingo-4.27,28 The LINGO-1 protein has a predominant
expression profile in the central nervous system (CNS), including
the brain and spinal cord, with no detectable level of expression in
non-neural tissues.29 Though little is known about Lingo-2, Lingo-3,
and Lingo-4, studies have revealed that they are present in far lower
levels in the CNS than LINGO-1.27,28 LINGO-1 is the co-receptor
of Nogo-66 receptor (NgR1) and lack of LINGO-1 will significantly
decrease the activity of the NgR1 signaling pathway. The
involvement of Lingo-2, 3, and 4 in this signaling pathway is
minimal.30
Human LINGO-1 has 614 amino acids.24,25 It contains both
leucine-rich repeat (LRR) and Ig-like domains in their extracellular
region followed by a transmembrane domain as well as a short
cytoplasmic tail (about 70 amino acids).25,29–31 The extracellular LRR
domain comprises 12 LRR flanked by an N terminal and a C terminal
capping domain.30,31 This extracellular LRR domain of LINGO-1
binds with the LRR domain of NgR1 and significantly influences the
activity of the NgR1 signaling pathway in the CNS.30,31 The LRR
domains of proteins have been implicated to have a role in protein–
protein interaction and their unique structure may help in cell
signaling and/or cell adhesion in specific regions of the brain.25,29–31
The C-terminal part of LINGO-1 has a short cytoplasmic tail with
about 70 amino acids.25,29–31 The cytoplasmic tail consists of a
canonical epidermal growth factor receptor (EGFR)-like tyrosine
phosphorylation site, which binds with EGFR and influences cellular
activity of the EGFR–PI3K–Akt signaling pathway in the CNS.32,33
Recent studies suggest that LINGO-1 could undergo oligomerization,
which may also be related to the physiological role of LINGO-1 in the
CNS.25
In human brain, higher levels of LINGO-1 expression are seen in
the hippocampus, thalamus and neocortex and lower levels of
expression are seen in the cerebellum and spinal cord.29 In situ
hybridization studies demonstrated that the mRNA of LINGO-1 could
be predominantly detected during embryonic and postnatal stages.29
The expression of LINGO-1 increases after CNS injury.34 All of these
findings suggest that LINGO-1 has some important unknown
neuronal functions in the CNS. LINGO-1 could be involved with
the inhibition of axon growth, disturbance of oligodendrocyte
differentiation and myelination, as well as influence neuron survival
via upregulation of the NgR1 signaling pathway and downregulation
of the EGFR-PI3K-Akt signaling pathway.32,35–37 The possible
pathological roles of LINGO-1 in ET as well as other neurodegenera-
tive diseases will be discussed.
LINGO-1 and Nogo-66 Receptor
LINGO-1 is a functional component of the NgR1 (a ligand-binding
subunit)/p75 or TROY (signal transducing subunits) signaling
complex in the CNS.30 In this complex, LINGO-1 binds with NgR1
and p75 or TROY proteins to form a ternary complex and functions
to facilitate the NgR1 signal pathway.30,35 However LINGO-1 has a
very low level of expression in non-neuronal cells. Lack of LINGO-1 in
non-neuronal cells contributes to inactivation of NgR1 even in the
presence of its binding ligands (inhibitory molecules such as MAG,
OMGp, and Nogo-66).30,35 In the CNS, activation of NgR1 by its
ligands can result in the displacement of Rho from the dissociation
inhibitor, thus activating RhoA.38,39 RhoA activation is a key event
and can activate its downstream Rho-associated protein kinase
(ROCK), leading to blockage of neurite outgrowth, disruption of
myelination of axons and inhibition of the maturation of oligoden-
drocytes.38–40 Activation of the NgR1/P75 or TROY signaling
pathway could inhibit neuron proliferation and might abrogate
neuron regeneration after injury.38 In contrast, targeted disruption of
endogenous LINGO-1 function can downregulate the activity of the
NgR1/P75 or TROY signaling pathway, block RhoA activation, and
may facilitate neurite outgrowth even in the presence of inhibitory
molecules.30,41–44
LINGO-1 and EGF Receptor
The PI3K-Akt signaling pathway is an important signaling pathway
downstream of EGFR.45,46 After binding with its ligands, EGFR forms
dimers, and is phosphorylated and activated.45,46 The activated EGFR
sends a signal to PI3K, which in turn propagates the signal and leads to
the phosphorylation of Akt (formation of p-Akt).45,46 The p-Akt is an
activated form of Akt that promotes cell survival and proliferation.45,46
The EGFR signaling pathway is related to survival and proliferation of
neurons and also is linked with neurodegenerative diseases.47–52 The
EGFR signaling pathway promotes proliferation, survival, and
migration of neuronal stem cells47,48 and protects post-mitotic
neuronal cells in vivo and in vitro against various stress-induced
injuries.49 The lack of the EGFR can induce neurodegeneration in
transgenic animals.51,52
Inhibition of LINGO-1 in glaucoma animal models could
upregulate p-Akt and rescue retinal ganglion cells (RGCs) from cell
death.53 Neuroprotection in LINGO-1 knockout mice is associated
with increased p-Akt.32 LINGO-1 could interact with EGFR directly,
while overexpression of LINGO-1 could induce dosage-dependent
downregulation of EFGR levels in cells.32 Therefore, LINGO-1 might
negatively regulate EGFR signaling pathways via accelerating EGFR
internalization and degradation, and therefore downregulates the
downstream PI3K-Akt signaling activity.32 This mechanism is related
to negative regulation of neuronal survival by LINGO-1. Hence
LINGO-1 antagonists (LINGO-1-Fc, dominant negative LINGO-1,
and anti-LINGO-1 antibody) might disrupt LINGO-1’s binding with
EGFR and increase EGFR levels in cells. This could contribute to
activation of the EGFR-PI3K-Akt signaling pathway and improve-
ment of Purkinje cell survival in cerebellum of ET.
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LINGO-1 Negatively Regulates Neuron Survival
Glaucoma (increased intraocular pressure) results in slow degenera-
tion of RGCs and their axons.55,56 In one study it was demonstrated
that blocking of LINGO-1 with a soluble version of the extracellular
domain of LINGO-1, LINGO-1-Fc fragment or primary antibody
against LINGO-1 in glaucoma animal models could up-regulate Akt
phosphorylation and rescue RGCs from cell death after ocular
hypertension and optic nerve transaction.53 Another study revealed
that LINGO-1 antagonism promotes functional recovery and axonal
sprouting after spinal cord injury.57 Furthermore LINGO-1 expres-
sion is present in midbrain dopaminergic neurons in human and
rodent brains.32 The expression level of LINGO-1 is elevated in the
substantia nigra (SN) of patients with Parkinson’s disease (PD)
compared with age-matched controls32 and in animal PD models
after neurotoxic damage.32 However in LINGO-1 knockout mice,
dopaminergic neuron survival is higher.32 This neuroprotection in
LINGO-1 knockout mice is accompanied by increased Akt phos-
phorylation (p-Akt).32 Both in vitro and in vivo data suggest that
blockage of LINGO-1 protects and enhances neurite growth of
midbrain neurons after blockage of LINGO-1.32 Thus there is a
negative link between LINGO-1 and dopaminergic neuron survival,
which might be related to pathological roles of LINGO-1 in Purkinje
cell degeneration in ET.
LINGO-1 Nnegatively Regulates Oligodendrocytes
Differentiation
LINGO-1 expression can be detected in neurons and in
oligodendrocytes.54 Inhibition of LINGO-1 activity in vitro and in vivo
promotes outgrowth of oligodendrocyte processes and leads to highly
developed myelinated axons.41,42,58 In contrast, overexpression of
LINGO-1 could contribute to delays in the onset of myelination.40
The maturation of oligodendocytes is vital to the myelination of
neuron axons and the neurotrophic support to neurons.59–61 These
functions are dependent on maturation of oligodendocytes and are
related to neuronal functions and even neuron survival in the
brain.59–61 The RhoA signaling pathway is related to oligodendrocyte
differentiation and myelination.62,63 LINGO-1 activates the RhoA
pathway and is a negative regulator of oligodendrocyte differentiation
and myelination.40,57 However, detailed molecular mechanisms
related to LINGO-1 induced inhibition of oligodendrocyte maturation
remains to be elucidated. These findings have stimulated much interest
in this molecule as a promising therapeutic target, in particular for the
treatment of neurodegenerative diseases and diseases associated with
myelin deficiencies, such as multiple sclerosis and leukodystrophies.
Possible Mechanisms of LINGO-1 Induced
Neurodegeneration in ET
Several reports of association, driven largely by different rs9652490
alleles, suggest that these LINGO-1 variants when combined with
other epigenetic and genetic factors possibly function to influence the
LINGO-1 expression profile.64 The expression level of LINGO-1 is
higher in dopaminergic neurons of PD patients.32 The expression level
of LINGO-1 also increases in PD animal models after neurotoxin
challenge32 and after CNS injury.54 Therefore, it would be interesting
to determine whether the expression level of LINGO-1 in the brains of
individuals carrying genetic variants of LINGO-1 is higher than that of
non-carriers. The identified risk variants of LINGO-1 are all located in
the introns of the LINGO-1 gene.65 The non-coding regions of genes
including introns can often function as regulatory sequences that affect
gene splicing, transcription, and translation.66 Intron variants could
also significantly influence gene expression levels and even contribute
to human disorders.67–70 Multiple variants of dopamine transporter
(DAT1) gene have been shown to influence DAT1 gene expression
and modulate susceptibility to bipolar disorder.67,68 An intronic
polymorphism is associated with increased XRCC1 gene expression
and leads to reduced apoptosis and familial breast cancer.
Furthermore the rs9939609 A variation of the fat mass and obesity-
associated (FTO) gene increases the mRNA level of the FTO gene.69
The intronic variants of the MEIS1 gene decreases expression of this
gene and is associated with restless legs syndrome.70 Therefore it is
possible that the intronic variants of LINGO-1 gene can lead to
increased expression level of LINGO-1 and contribute to ET in the
presence of other factors including oxidative stress and environmental
neurotoxins.
Increase in LINGO-1 expression might negatively regulate cell
viability of Purkinje neurons due to downregulation of EGFR-PI3K-
Akt signaling. The increased expression level of LINGO-1 can lead to
inhibition of oligodendrocyte differentiation via activation of NgR1
signaling. The impaired oligodendocyte maturation will impair the
neurotrophic support of oligodendocytes to Purkinje cells and disrupt
the myelination of axons of Purkinje neurons in the cerebellum. All of
these mechanisms might converge and contribute to Purkinje cell
degeneration. Furthermore, LINGO-1 can activate the NgR1
signaling pathway, while activation of the NgR1 signaling pathway is
found to prohibit neurogenesis in brain.71,72 This could contribute to
decreased numbers of Purkinje cells in cerebellum to replace
degenerated neurons. The potential mechanisms of LINGO-1-induced
Purkinje neuron degeneration are summarized in Figure 1.
Discussion
LINGO-1, the key negative regulator of the oligodendrocyte
differentiation, has been considered to be a potential therapeutic
target for CNS disorders, including degenerative diseases and CNS
injury. We have discussed various hypotheses as to how LINGO-1
could be involved in the pathophysiology of ET. However, additional
clinical and in vivo studies will be required to further decipher the role
LINGO-1 in neurodegeneration. Future post-mortem studies to
determine the expression levels of LINGO-1 in Purkinje cells in the
cerebellum of LINGO-1 variants carriers with or without ET
compared with age-matched healthy control subjects might be helpful
to answer the question whether genetic variants of LINGO-1 lead to
an increased expression of LINGO-1 in Purkinje cells. Transgenic
LINGO-1 animal models overexpressing the LINGO-1 risk variants
will also be useful. This is based on the presumption that the identified
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risk variants are the actual causative variants. However, all the
identified risk variants are located in introns and it is not clear if these
risk variants could influence the splicing of the LINGO-1 gene or have
an effect on LINGO-1 protein translation. This will be the challenge
for developing LINGO-1 genetic variant animal models. Long-term
longitudinal clinical, imaging, and neurophysiologic studies to evaluate
asymptomatic LINGO-1 variant carriers to assess their symptom onset
and clinical progression will be useful to determine the penetrance and
pathogenicity of these LINGO-1 risk variants. Potential neuroprotec-
tive drug trials targeting suitable molecular targets, such as LINGO-1,
may offer hope to ET patients.
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